News & Updates
Filter by Specialty:
Dual-target oral drug outperforms tofacitinib in RA treatment
The novel, highly selective dual JAK1/TYK2 inhibitor TLL-018 appears to have better efficacy than the currently approved JAK inhibitor tofacitinib in the treatment of patients with rheumatoid arthritis (RA), according to the results of a head-to-head trial presented at EULAR 2023.
Dual-target oral drug outperforms tofacitinib in RA treatment
19 Jun 2023
New-onset vs long-standing diabetes tied to higher pancreatic cancer risk
People with diabetes mellitus (DM) have a higher risk of pancreatic cancer than those without DM, reveals a recent study. Among diabetic individuals, those with new-onset DM show a greater pancreatic cancer risk than those with long-standing DM.
New-onset vs long-standing diabetes tied to higher pancreatic cancer risk
19 Jun 2023
Updated CodeBreak 200 analyses boost sotorasib role in KRASG12C-mutant NSCLC
In the PRO analyses of the phase III CodeBreak 200 trial, the first-in-class KRASG12C inhibitor sotorasib improved quality of life (QoL) of patients with pretreated KRASG12C-mutated advanced non-small-cell lung cancer (NSCLC) compared with docetaxel.
Updated CodeBreak 200 analyses boost sotorasib role in KRASG12C-mutant NSCLC
19 Jun 2023
Maternal OCD tied to adverse pregnancy, delivery, neonatal outcomes
Pregnant women with obsessive–compulsive disorder (OCD) are at higher risk of adverse pregnancy, delivery, and neonatal outcomes, including gestational diabetes, pre-eclampsia, caesarean delivery, preterm birth, neonatal respiratory distress, neonatal infections, and major congenital malformations, among others, as reported in a study.
